Rodman & Renshaw has published a research report on Stryker Corporation SYK upgrading the medical device developer from Market Perform to Market OutPerform.
In the report, Rodman & Renshaw wrote, "We are upgrading Stryker to a Market OutPerform rating and a 12-month PT of $56. Our PT is derived using a relative valuation methodology of forward P/E. Stryker, based on a historical analysis since 2005 has usually traded at a 15% premium on a forward basis to the broader medtech universe P/E."
Rodman & Renshaw upgraded Stryker from Market Perform to Market OutPerform with a price target of $56. Stryker closed Friday at $48.54.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in